THE PHENOMENON OF «NO-REFLOW» ― A MODERN VIEW OF THE PROBLEM. THE PLACE BLOCKERS GLYCOPROTEIN IIb/IIIa RECEPTOR IN THE PREVENTION OF THIS CONDITION
Keywords:
primary percutaneous coronary intervention, reperfusion, blockers glycoprotein IIb/IIIa re¬ceptors, phenomenon of «no-reflow», microcirculatory blood flow, myocardial blush grade, myocardial in¬farction
Abstract
For mechanical reperfusion using as primary percutaneous coronary intervention (PPCI) and at pharmacoinvasive strategy requires a clear compliance with the time intervals that is an important moment in the treatment of myocardial infarction-segment elevation ST (MI ST). However, it should be noted that a large proportion of patients who in the time frame set was performed reperfusion therapy with thrombolytic or PCI restoring blood flow is achieved only at the epicardial vessels, i.e. developed the so-called phenomenon of «no-reflow» or the phenomenon of «no blood flow recovery». Proved that in the development of the state play a role once 4 pathogenetic factors that complicates diagnosis and treatment of the phenomenon of «no-reflow». Largest proven positive effect for preventing the development of the phenomenon of «no-reflow» have blockers GP IIb/IIIa receptor.Downloads
Download data is not yet available.
References
1. Giampaolo Niccoli. Myocardial No-Reflow in Humans / Giampaolo Niccoli, Francesco Burzotta, Leonar-da Galiuto and Filippo Crea // doi : 10.1016/j.jacc. ― 2009.03.054 J. Am. Coll. Cardiol. ― 2009. ― № 54. ― Р. 281―292.
2. Lincoff A. M. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? / A. M. Lincoff, E. J. Topol // Circulation. ― 1993. ― № 88. ― Р. 1361―1374.
3. Коваль М. Феномен «no-reflow» ― ложка дегтя в бочке меда реваскуляризаци / М. Коваль // Medicine Review. ― 2008. ― № 5 (05). ― Р. 32―36.
4. Predictive Factors and Impact of No-Reflow After Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction / [Gjin Ndrepepa, Klaus Tiroch, Dritan Keta, Massimiliano Fusaro, Melchior Seyfarth, Jürgen Pache, Julinda Mehilli, Albert Schömig, Adnan Kastrati] // Deutsches Herzzentrum München, Technische Universität, Munich, Germany.
5. Collet J. P. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes / Collet J. P., Montalescot G. // Diabetes Vasc Dis Res. ― 2005. ― № 2. ― Р. 136―143.
6. Golino P. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion / Golino P., Maroko P. R., Carew T. E. // Circulation. ― 1987. ― № 75. ― Р. 292―298.
7. Franz Weidinger «No-reflow» / Franz Weidinger // Second medical department hospital Rudolfstiftung, Vienna Austria, ESC Stockholm, 30 August 2010.
8. Thorsten Reffelmann. The «no-reflow phenomenon : basic science and clinical correlates» / Thorsten Reffelmann, Robert A Kloner // Heart. ― 2002. ― № 87. ― Р. 162―168. ― doi:10.1136/heart.87.2.162 Education in Heart.
9. Nature Clinical Practice Cardiovascular Medicine (2006) 3, 499-506; Received 16 January 2006. Accepted 6 June 2006 No-reflow phenomenon and prognosis in patients with acute myocardial infarction Correspondence Division of Cardiology, Sakurabashi Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-001, Japan.
10. Robert A. Kloner. «Glycoprotein IIb/IIIa inhibitors and no-reflow» doi:10.1016/j.jacc.2003. 11.005 / Robert A. Kloner, Wangde Dai. // J. Am. Coll. Cardiol. ― 2004. ― № 43. ― Р. 284―286.
11. Albert J. Deibele, MD; Lisa K. Jennings, PhD; James E. Tcheng, MD; Cathy Neva, RN, CCRC; Angela D. Earhart, BS; C. Michael Gibson, MS, MD Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function The Intracoronary Eptifibatide (ICE) Trial Received June 1, 2009; accepted November 23, 2009.
2. Lincoff A. M. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? / A. M. Lincoff, E. J. Topol // Circulation. ― 1993. ― № 88. ― Р. 1361―1374.
3. Коваль М. Феномен «no-reflow» ― ложка дегтя в бочке меда реваскуляризаци / М. Коваль // Medicine Review. ― 2008. ― № 5 (05). ― Р. 32―36.
4. Predictive Factors and Impact of No-Reflow After Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction / [Gjin Ndrepepa, Klaus Tiroch, Dritan Keta, Massimiliano Fusaro, Melchior Seyfarth, Jürgen Pache, Julinda Mehilli, Albert Schömig, Adnan Kastrati] // Deutsches Herzzentrum München, Technische Universität, Munich, Germany.
5. Collet J. P. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes / Collet J. P., Montalescot G. // Diabetes Vasc Dis Res. ― 2005. ― № 2. ― Р. 136―143.
6. Golino P. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion / Golino P., Maroko P. R., Carew T. E. // Circulation. ― 1987. ― № 75. ― Р. 292―298.
7. Franz Weidinger «No-reflow» / Franz Weidinger // Second medical department hospital Rudolfstiftung, Vienna Austria, ESC Stockholm, 30 August 2010.
8. Thorsten Reffelmann. The «no-reflow phenomenon : basic science and clinical correlates» / Thorsten Reffelmann, Robert A Kloner // Heart. ― 2002. ― № 87. ― Р. 162―168. ― doi:10.1136/heart.87.2.162 Education in Heart.
9. Nature Clinical Practice Cardiovascular Medicine (2006) 3, 499-506; Received 16 January 2006. Accepted 6 June 2006 No-reflow phenomenon and prognosis in patients with acute myocardial infarction Correspondence Division of Cardiology, Sakurabashi Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-001, Japan.
10. Robert A. Kloner. «Glycoprotein IIb/IIIa inhibitors and no-reflow» doi:10.1016/j.jacc.2003. 11.005 / Robert A. Kloner, Wangde Dai. // J. Am. Coll. Cardiol. ― 2004. ― № 43. ― Р. 284―286.
11. Albert J. Deibele, MD; Lisa K. Jennings, PhD; James E. Tcheng, MD; Cathy Neva, RN, CCRC; Angela D. Earhart, BS; C. Michael Gibson, MS, MD Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function The Intracoronary Eptifibatide (ICE) Trial Received June 1, 2009; accepted November 23, 2009.
How to Cite
Kopitsa, N. P., & Vishnevskaya, I. R. (1). THE PHENOMENON OF «NO-REFLOW» ― A MODERN VIEW OF THE PROBLEM. THE PLACE BLOCKERS GLYCOPROTEIN IIb/IIIa RECEPTOR IN THE PREVENTION OF THIS CONDITION. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (22), 17-21. Retrieved from https://periodicals.karazin.ua/medicine/article/view/6869
Issue
Section
Philosophy of medicine
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
